Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9P2W7
UPID:
B3GA1_HUMAN
Alternative names:
Beta-1,3-glucuronyltransferase 1; Glucuronosyltransferase P; UDP-GlcUA:glycoprotein beta-1,3-glucuronyltransferase
Alternative UPACC:
Q9P2W7; B7Z5Z8; Q96FS7
Background:
Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1, also known as Beta-1,3-glucuronyltransferase 1, plays a pivotal role in the biosynthesis of L2/HNK-1 carbohydrate epitope on glycoproteins. It is instrumental in glycosaminoglycan biosynthesis, acting on substrates like asialo-orosomucoid and asialo-fetuin. Its activity is contingent upon the presence of sphingomyelin, particularly those with saturated fatty acids.
Therapeutic significance:
Understanding the role of Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 could open doors to potential therapeutic strategies.